A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
Status:
Unknown status
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and efficacy (benefits) of an investigational
drug LB-100, for treatment of myelodysplastic syndromes. LB-100 has previously been
administered to patients with various solid tumors. In this study, LB-100 will be
administered as an intravenous infusion over 120 minutes. This study will be conducted in 2
phases. In phase Ib, escalating doses of LB-100 will be administered to patients to study the
safety and to determine a safe dose of LB-100. In phase 2, patients will be administered
LB-100 at the dose that was found to be safe in phase Ib. The efficacy (benefits) and safety
of LB-100 will be determined in this phase of the study.